EGFR and metastatic neoplasm: Despite a response of short duration in patients with mCRC, the inclusion of anti-EGFR therapy to chemotherapy with FOLFOX or FOLFIRI has been shown to increase response rates and convert patients with inoperable liver disease to potentially resectable metastatic disease [30].